Sugi Predict

Sugi Predict / Compounds / SCHEMBL1986001

SCHEMBL1986001

SCHEMBL1986001

COC(=O)c1c(C)nc(Cl)nc1Nc1cccc(C)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NFKB1 P19838 1/20 0.51
▸ TP53 P04637 2/20 0.47
▸ LMNA P02545 1/20 0.47
▸ TSHR P16473 1/20 0.47
▸ MAPK1 P28482 1/20 0.47
▸ MAPT P10636 3/20 0.45
▸ L3MBTL1 Q9Y468 1/20 0.45
▸ POLB P06746 1/20 0.44
▸ EGFR P00533 1/20 0.44
▸ KDM4E B2RXH2 1/20 0.43
▸ RAB9A P51151 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ ALDH1A1 P00352 1/20 0.43
▸ HPGD P15428 1/20 0.43
▸ CA12 O43570 1/20 0.43
▸ CA1 P00915 1/20 0.43
▸ CA2 P00918 1/20 0.43
▸ CA9 Q16790 1/20 0.43
▸ CISD2 Q8N5K1 1/20 0.42
▸ SYK P43405 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1989865 0.90 NFKB1 (0.51) NFKB1TP53LMNATSHRMAPK1
SCHEMBL21707239 0.87 HPGD (0.49) NFKB1TP53LMNATSHRMAPK1
SCHEMBL25401906 0.84 MEN1 (0.48) TP53MAPTPOLBEGFRKDM4E
SCHEMBL1988610 0.83 LMNA (0.48) TP53LMNATSHRMAPK1MAPT
SCHEMBL12640925 0.81 CISD2 (0.46) NFKB1TP53LMNATSHRMAPK1
SCHEMBL17054935 0.80 MAPT (0.51) TP53MAPTPOLBEGFRKDM4E
SCHEMBL1989756 0.80 NFKB1 (0.54) NFKB1TP53MAPTL3MBTL1POLB
SCHEMBL1986224 0.78 FER (0.46) NFKB1TP53LMNATSHRMAPK1
SCHEMBL22475361 0.78 SYK (0.49) TP53LMNATSHRMAPK1MAPT
SCHEMBL12640800 0.78 TP53 (0.55) TP53LMNATSHRMAPK1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230295171-A1 FUSED HETEROAROMATIC PYRROLIDINONES WELLS THERAPEUTICS, INC. 2023-09-21 — — US disclosed
US-20230295171-A1 FUSED HETEROAROMATIC PYRROLIDINONES WELLS THERAPEUTICS, INC. 2023-09-21 — — US disclosed
US-20230295171-A1 FUSED HETEROAROMATIC PYRROLIDINONES WELLS THERAPEUTICS, INC. 2023-09-21 — — US disclosed
US-20220306634-A1 FUSED HETEROAROMATIC PYRROLIDINONES TAKEDA SAN DIEGO, INC. 2022-09-29 — — US disclosed
EP-3825316-A1 FUSED HETEROAROMATIC PYRROLIDINONES AS SYK INHIBITORS Takeda Pharmaceutical Company Limited (JP) 2021-05-26 — — EP disclosed
EP-3825316-A1 FUSED HETEROAROMATIC PYRROLIDINONES AS SYK INHIBITORS Takeda Pharmaceutical Company Limited (JP) 2021-05-26 — — EP disclosed
EP-3489236-B1 PROCESS FOR THE PREPARATION OF FUSED HETEROAROMATIC PYRROLIDINONES TAKEDA PHARMACEUTICALS CO (JP) 2020-09-30 — — EP disclosed
EP-3489236-B1 PROCESS FOR THE PREPARATION OF FUSED HETEROAROMATIC PYRROLIDINONES TAKEDA PHARMACEUTICALS CO (JP) 2020-09-30 — — EP disclosed
EP-3489236-A1 PROCESS FOR THE PREPARATION OF FUSED HETEROAROMATIC PYRROLIDINONES Takeda Pharmaceutical Company Limited (JP) 2019-05-29 — — EP disclosed
EP-3489236-A1 PROCESS FOR THE PREPARATION OF FUSED HETEROAROMATIC PYRROLIDINONES Takeda Pharmaceutical Company Limited (JP) 2019-05-29 — — EP disclosed
US-8440689-B2 Fused heteroaromatic pyrrolidinones TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-14 — — US disclosed
US-20130116260-A1 FUSED HETEROAROMATIC PYRROLIDINONES AS SYK INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-09 — — US disclosed
US-20130116260-A1 FUSED HETEROAROMATIC PYRROLIDINONES AS SYK INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-09 — — US disclosed
US-20130116260-A1 FUSED HETEROAROMATIC PYRROLIDINONES AS SYK INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-09 — — US disclosed
EP-2516434-A1 FUSED HETEROAROMATIC PYRROLIDINONES AS SYK INHIBITORS Takeda Pharmaceutical Company Limited (JP) 2012-10-31 — — EP disclosed
WO-2011079051-A1 FUSED HETEROAROMATIC PYRROLIDINONES AS SYK INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-30 — — WO disclosed
WO-2011079051-A1 FUSED HETEROAROMATIC PYRROLIDINONES AS SYK INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-30 — — WO disclosed
US-20110152273-A1 FUSED HETEROAROMATIC PYRROLIDINONES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-23 — — US disclosed
US-20110152273-A1 FUSED HETEROAROMATIC PYRROLIDINONES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-23 — — US disclosed
US-20110152273-A1 FUSED HETEROAROMATIC PYRROLIDINONES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220306634-A1 FUSED HETEROAROMATIC PYRROLIDINONES SYK, ZAP70, LYN NFKB1 233/4885TP53 25/4885LMNA 4615/4885
US-20130116260-A1 FUSED HETEROAROMATIC PYRROLIDINONES AS SYK INHIBITORS SYK, BTK, LYN NFKB1 227/4885TP53 31/4885LMNA 4650/4885
US-20110152273-A1 FUSED HETEROAROMATIC PYRROLIDINONES SYK, ZAP70, LYN NFKB1 233/4885TP53 25/4885LMNA 4615/4885
US-20230295171-A1 FUSED HETEROAROMATIC PYRROLIDINONES SYK, ZAP70, LYN NFKB1 233/4885TP53 25/4885LMNA 4615/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.